Sagar Bhagwat, MBA, MS

CRS:

BJMC

Role:

Administrative and Finance

Position:

Senior Grants and Contracts Analyst

Mr. Bhagwat is the Senior Grants and Contracts Analyst for Johns Hopkins Center for Clinical Global Health Education (CCGHE) and manages the financial activities of the center along with the Fiscal Operations Manager. He works on all aspects of sponsored research pre and post award, including development and management of federal, state, private, and foundation grants/contracts. He is the primary contact for all outgoing CCGHE subcontracts and works closely with international collaborators in India, Uganda, United Kingdom as well as domestic collaborators within the US.
 
Mr. Bhagwat is a part of the CCGHE leadership group that provides financial/administrative support and oversight to the Johns Hopkins entities in India (Johns Hopkins India Pvt. Ltd & Johns Hopkins India Foundation). He works closely with external funding agencies such as US National Institutes of Health (NIH), CRDF Global, Maryland Department of Health (MDH) among others and internally with the Office of Research Administration (ORA), the Office of Sponsored Projects and Shared Services (SPSS), the Department Finance Office at the Johns Hopkins University School of Medicine.
 
He joined Johns Hopkins in 2016 with several years of accounting and finance experience. He received a dual Master’s degree in Business Administration (MBA in Operations Management) and Science (MS in Chemical & Biomedical Engineering) from the Cleveland State University.

Categories

Leadership Committees
CRS
Roles

Clinical Trials

NWCS 445: Novel Biomarkers to Shorten TB Treatment

Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...

Read More

A5300/P2003: PHOENIx Feasibility Study

Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design

Read More

A5273: Multicenter Study of Options for Second-Line...

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

Read More

A5314: Effect of LDMTX on Inflammation in HIV-infected...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Read More

P1077FF: Formula Feeding Version of the PROMISE Study...

1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More